Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cynata Therapeutics Ltd

CYP.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: BUY

Last Close

$0.01

▲ +0.00%

Market Cap $1.89M · Vol 82.94K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.89M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

50.00

Momentum

Beta

0.95

vs Market

52W High

$0.31

97.34% below

52W Low

$0.01

2.67% above

Volume

82.94K

Avg 805.71K

P/B

5.67

Price-to-book

ROE

N/A

Return on equity

Free Float

75.03%

Public shares

Shariah Compliance8 STANDARDS

✗ Cynata Therapeutics Ltd (CYP.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CYP.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.33%

-15.38%

-96.56%

-97.03%

YTD

-96.81%

-94.63%

-91.68%

-97.82%

Financials & Valuation

TTM · Annual

Total Revenue	$149.83K
Net Income	$-6,178,995.00
Revenue Growth (YoY)	-28.63%
Gross Margin	100.00%
Operating Margin	-4,948.78%
Net Profit Margin	-4,124.12%
ROE	N/A
ROA · ROIC	-120.50% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	135.01
P/B	5.67
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	243.45M

Technical Indicators

50-Day SMA	$0.04
200-Day SMA	$0.18
RSI (14)	50.00
Beta	0.95
52-Week High	$0.31
52-Week Low	$0.01

Volume Today	82.94K
Avg Daily Volume (30D)	805.71K
Relative Volume	0.10x
Volatility (10D)	90.06
Volatility (30D)	124.17
Free Float	75.03%

Analyst Consensus

BUY

Current Price $0.01

Mean Target N/A

52W Low$0.01 52W High$0.31

Current

Target

$0.01 $0.31

Current Analyst target

· 1 analysts

Identifiers

ExchangeASX

FIGIBBG001T09MY0

ISINAU000000CYP7

CountryAustralia

Sub-IndustryBio Therapeutic Drugs

Earnings DateJul 31, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells (iPSCs) to manufacture cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale. Its product candidates include CYP-001, CYP-004 and CYP-006TK. CYP-001 is under Phase II clinical trials with a focus on treatment for steroid-resistant acute graft versus host disease (GvHD) and a Phase 1/II trial in patients undergoing kidney transplantation. CYP-006TK is a Cymerus iPSC-derived MSC topical wound dressing product candidate. This product is used in the Company’s Phase I clinical trial in diabetic foot ulcers (DFU). CYP-004, is an iPSC-derived MSC product for intra-articular injection (injection into a joint), is ongoing with a Phase III trial in patients with osteoarthritis of the knee.